Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 9/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.37 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.37 |
| ▸ | VNN1 | O95497 | 3/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20162161 | 0.91 | RIPK1 (0.40) | RIPK1TAS2R8 | |
| SCHEMBL20162175 | 0.91 | TAS2R8 (0.39) | RIPK1TAS2R8 | |
| SCHEMBL20162113 | 0.89 | TAS2R8 (0.45) | RIPK1CYP3A4SLC6A9KCNH2SLC6A5 | |
| SCHEMBL20162150 | 0.88 | HTR2C (0.46) | RIPK1TAS2R8 | |
| SCHEMBL20162174 | 0.87 | HTR2C (0.43) | RIPK1TAS2R8 | |
| SCHEMBL20162162 | 0.87 | TAS2R8 (0.38) | RIPK1TAS2R8 | |
| SCHEMBL20162110 | 0.86 | KDM4C (0.45) | CYP3A4KCNH2TAS2R8 | |
| SCHEMBL20162116 | 0.86 | TAS2R8 (0.39) | RIPK1TAS2R8 | |
| SCHEMBL20162155 | 0.85 | TAS2R8 (0.40) | RIPK1TAS2R8 | |
| SCHEMBL20169996 | 0.83 | HTR2C (0.46) | RIPK1TAS2R8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-05-21 | — | — | US | claimed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | claimed |
| EP-3323809-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2018-05-23 | — | — | EP | claimed |
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-05-21 | — | — | US | disclosed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| EP-3323809-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2018-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | NR0B1, NR2E1, NR0B2 | RIPK1 3470/4885CYP3A4 1261/4885SLC6A9 4268/4885 |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | NR0B1, NR2E1, NR0B2 | RIPK1 3470/4885CYP3A4 1261/4885SLC6A9 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.